Sitagliptin/metformin extended-release

Drug Profile

Sitagliptin/metformin extended-release

Alternative Names: Januet XR; Janumet XR; Metformin extended-release/sitagliptin; Metformin XR/sitagliptin; MK-0431A XR; Sitagliptin/metformin XR

Latest Information Update: 17 Apr 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antihyperglycaemics; Biguanides; Insulin sensitisers; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 07 Apr 2017 Merck receives complete response letter from the FDA for sitagliptin/metformin extended-release treatment of patients with Type 2 diabetes mellitus
  • 25 Sep 2015 Merck has patent protection for sitagliptin/metformin XR in USA (Merck 10-K, September 2015)
  • 03 Jun 2015 Launched for Type-2 diabetes mellitus in Israel, Malaysia, Singapore, Hong Kong and India (PO) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top